MedStar Georgetown Awarded Another International Accreditation for Stem Cell and Bone Marrow Transplantation
Program is the Only One FACT Accredited in the Washington, D.C. Metropolitan Area
January 15, 2018
Explore By Category :
- Blood Management
- Cancer
- Cardiology
- Emergency medicine/trauma
- Endocrinology
- Gastroenterology/digestive diseases
- Healthcare industry
- Innovation
- Interventional Pulmonology
- Interventional Radiology
- Medical Education
- MedStar in the community
- Neurosciences
- Nursing
- Oncology
- Orthopaedics and sports medicine
- Orthopedic
- Pediatrics
- Primary care
- Quality and Patient Safety
- Rehabilitation
- Research
- Stem Cell Transplant and Cellular Immunotherapy
- Technology/IT
- Transplant
- Transplantation
- Women’s services
- Video Gallery
- MedStar Washington Hospital Center News
- MedStar Harbor Hospital News
- MedStar Good Samaritan Hospital News
- MedStar Franklin Square Medical Center News
- MedStar Union Memorial Hospital News
- MedStar Montgomery Medical Center News
- MedStar St. Mary's Hospital News
- MedStar Health System News
- MedStar Southern Maryland Hospital Center News
The MedStar Georgetown University Hospital Stem Cell Transplant and Cellular Immunotherapy Program has earned internationally-recognized accreditation to now provide the full range of the newest treatment options for patients who need bone marrow or stem cell transplantation. The latest recognition from the Foundation for the Accreditation of Cellular Therapy (FACT) accredits MedStar Georgetown to use donor bone marrow or stem cells for what’s called allogeneic transplantation to treat certain blood cancers or other diseases. The program earned FACT accreditation for patients using their own cells, also known as autologous transplantation in 2015.
In addition, the program earned accreditation to provide cell-based immunotherapies, such as the rapidly developing treatments using autologous CAR T-cells in the treatment of lymphoma, leukemia, and multiple myeloma.
FACT accreditation is internationally-recognized and awarded to programs that prove to be compliant with the latest and most stringent industry standards, which are defined by leading experts in cellular therapy.
MedStar Georgetown has the only FACT accredited adult stem cell and cellular immunotherapy program in the metropolitan Washington, D.C. area.
“I’m really proud of our team’s hard work in meeting these rigorous requirements to achieve excellence in all different types of bone marrow transplantation,” said Scott Rowley, MD, FACP, director of the Stem Cell Transplant and Cellular Immunotherapy Program at MedStar Georgetown. “Everything we do is in an effort to bring the highest quality of care to our patients.”
Dr. Rowley’s team submitted evaluation documentation and underwent a thorough onsite inspection to attain FACT accreditation.
“Our accreditation for donor bone marrow or stem cell transplantation and cellular immunotherapy now provides these highly effective treatments to residents of the D.C. metropolitan region, and marks a major milestone in the growth of our program. Allogeneic transplants require the highest level of proficiency and clinical expertise, and earning FACT accreditation recognizes the quality of care provided at MedStar Georgetown,” says Dr. Rowley.
In addition to successfully passing standards for both autologous and allogeneic transplantation and immune effector cell therapy, MedStar Georgetown also received accreditation for marrow and peripheral blood stem cell collection, and for laboratory processing of cellular therapy products.
The Stem Cell and Cellular Therapy Program at MedStar Georgetown is a close collaboration with specialists from the John Theurer Cancer Center of Hackensack Meridian Health, one of the nation’s 10 largest stem cell transplant programs, and is a key component of the Lombardi Comprehensive Cancer Center, the only cancer center in the region to be designated by the National Cancer Institute as a Comprehensive Cancer Center.
The three-year FACT accreditation for the MedStar Georgetown Bone Marrow and Stem Cell Transplant Clinical Program is effective February 24, 2018.
Media Contact
Marianne Worley
Director of Media Relations
Office: 703-558-1287
Pager: 202-405-2824
[email protected]
Back to Top
Related News

MedStar Georgetown University Hospital acquires first and only robotic navigation system for spine surgery in Washington, D.C., region
Category : Innovation ,

MedStar Georgetown University Hospital named one of the Best Maternity Care Hospitals in the U.S.
Category : Education , Pediatrics , Women’s services ,

Inflammasome activation linked to T-cell dysregulation and poor outcomes in comorbid COVID-19 patients, according to MedStar Georgetown Transplant Institute led study
Category : Transplant ,

MedStar Georgetown Transplant Institute Implemented New Transplant Protocol and Performed More Kidney Transplants than any Other Hospital in U.S. During COVID-19 Pandemic.
Category : Healthcare industry , Quality and Patient Safety , Transplant ,

MedStar Georgetown University Hospital receives 5th Beacon Award for Excellence from American Association of Critical-Care Nurses
Category : Emergency medicine/trauma , Quality and Patient Safety ,

Study shows Retzius-sparing robotic prostatectomy at MedStar Georgetown University Hospital improves patient quality of life without compromising cancer control
Category : Healthcare industry , Innovation , Oncology ,

MedStar Georgetown University Hospital, first in Washington Metropolitan Area to offer promising investigational treatment for COVID-19
Category : Emergency medicine/trauma , Medical Education , MedStar in the community , Primary care , Research ,